ArticleJournal of biomedical nanotechnology2016
Gold Nanosphere Gated Mesoporous Silica Nanoparticle Responsive to Near-Infrared Light and Redox Potential as a Theranostic Platform for Cancer Therapy.
Article in Journal of biomedical nanotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 71 citations in OpenAlex.
- Synthesis of novel hybrid mesoporous gold iron oxide nanoconstructs for enhanced catalytic reduction and remediation of toxic organic pollutants.RSC advances · 2022Article
- Gold-based hybrid nanostructures: more than just a pretty face for combinational cancer therapy.Biophysical reviews · 2022Review
- Physically stimulus-responsive nanoparticles for therapy and diagnosis.Frontiers in chemistry · 2022Review
- Nanoparticle Systems for Cancer Phototherapy: An Overview.Nanomaterials (Basel, Switzerland) · 2021Review
- Improving anti-cancer drug delivery performance of magnetic mesoporous silica nanocarriers for more efficient colorectal cancer therapy.Journal of nanobiotechnology · 2021Article
- Inflammation during Lung Cancer Progression and Ethyl Pyruvate Treatment Observed by Pulmonary Functional HyperpolarizedContrast media & molecular imaging · 2021Article
- Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review.Advances in therapy · 2020Review
- Advances in redox-responsive drug delivery systems of tumor microenvironment.Journal of nanobiotechnology · 2018Review
- Photosensitizer Micelles Together with IDO Inhibitor Enhance Cancer Photothermal Therapy and Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018Article
- Article
- Mussel-inspired PLGA/polydopamine core-shell nanoparticle for light induced cancer thermochemotherapy.Acta biomaterialia · 2017Article
- Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics.Advanced drug delivery reviews · 2017Review
- Gold nanoparticles enlighten the future of cancer theranostics.International journal of nanomedicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
A gold/mesoporous silica hybrid nanoparticle (GoMe), which possesses the best of both conventional gold nanoparticles and mesoporous silica nanoparticles, such as excellent photothermal converting ability as well as high drug loading capacity and triggerable drug release, has been developed. In contrast to gold nanorod and other heat generating gold nanoparticles, GoMe is photothermal stable and can be repetitively activated through NIR irradiation. Doxorubicin loaded GoMe (DOX@GoMe) is sensitive to both NIR irradiation and intracellularly elevated redox potential. DOX@GoMe coupled with NIR irradiation exhibits a synergistic effect of photothermal therapy and chemotherapy in killing cancer cells. Furthermore, 64Cu-labeled GoMe can successfully detect the existence of clinically relevant spontaneous lung tumors in a urethane-induced lung cancer mouse model through PET imaging. Altogether, GoMe can be utilized as an effective theranostic platform for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.